Funded Tech Companies
Spexis
Wondering who provided funding to Spexis? SPRIM Global Investments joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
Spexis
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Hegenheimermattweg 125
Allschwil, CH-4123
CH
Allschwil, CH-4123
CH
Phone
Website
Email Address
Company Background Information
Overview
Spexis is generating hope for rare disease & oncology patients by targeting critical unmet treatment needs and difficult-to-drug structures. Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer. The most advanced of our four clinical candidates (Phases 1-3) is ColiFin®, an inhaled therapeutic for cystic fibrosis, is already approved and marketed in Europe and will be entering global pivotal P3 studies in early 2023. Furthermore, we apply our leading macrocyclic technology platform, the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. With our pipeline of potentially transformative product candidates, we aim to deliver substantial benefits to patients and meaningful value to society and our stakeholders.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
8/15/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Wager
Chief Financial Officer
Hernan Levett
Chief Medical Officer
Juergen Froehlich
Company Investors
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs